GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma
Seoul, Korea, & Redwood City, California, 17 January 2023 – GPCR Therapeutics, Inc., a venture-backed, clinical stage, international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, announced today the initiation of their phase 2 trial in the US for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers.
